Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of May 21, 2026, PTGX trades at $100.71 with a market cap of $6.48B and a P/E ratio of -55.44. PTGX moved +2.53% today. Year to date, PTGX is +19.84%; over the trailing twelve months it is +116.43%. Its 52-week range spans $33.31 to $107.84. Analyst consensus is strong buy with an average price target of $117.00. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PTGX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. PTGX recently traded at $100.71. Market cap is $6.48B. P/E ratio is -55.44. Revenue is $74.06M.
| Metric | Value |
|---|---|
| Price | $100.71 |
| Market Cap | $6.48B |
| P/E Ratio | -55.44 |
| EPS | $-1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $107.84 |
| 52-Week Low | $33.31 |
| Volume | 295.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $74.06M |
| Net Income | $-114.71M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.02M | $-130.15M | $-2.05 |
| 2023 | $60.00M | $-78.95M | $-1.39 |
| 2022 | $26.58M | $-127.39M | $-2.60 |
| 2021 | $27.36M | $-125.55M | $0.00 |
11 analysts cover PTGX: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.00.